On June 27, 2024, Jiangsu-based TransThera Sciences (Nanjing), Inc., also known as "药捷安康", submitted a prospectus to the Hong Kong Stock Exchange and plans to be listed on the main board of the exchange. This is their second attempt after their application was invalidated on August 25, 2021.
Link to the Prospectus of Pharma Block Sciences: https://www1.hkexnews.hk/app/sehk/2024/106575/documents/sehk24062702052_c.pdf Pharma Block Sciences, established in 2014, is a biopharmaceutical company that focuses on the discovery and development of innovative small molecule therapies for tumors, inflammation, and cardiovascular diseases based on clinical needs and is currently in the registration stage. Pharma Block Sciences has currently established six clinical candidate products and one preclinical candidate product pipeline, and the company plans to continue to expand its pipeline. The core product of Pharma Block Sciences, Tinengotinib (TT-00420), as a registered clinical-stage and potentially globally pioneering MTK inhibitor (mainly targeting FGFR/VEGFR, JAK, and Aurora kinases), has the potential to treat various relapsed or intractable, drug-resistant solid tumors (including cholangiocarcinoma, prostate cancer, breast cancer, biliary tract cancer and pan-FGFR solid tumors) to meet these unmet clinical needs. Tinengotinib has been granted China's National Medical Products Administration's breakthrough therapy designation and FDA's Fast-Track Designation for treatment of cholangiocarcinoma, as well as FDA's orphan drug designation for treatment of cholangiocarcinoma and EMA's orphan drug designation for treatment of biliary tract cancer. In addition to the core products, the company is also advancing several clinical projects for tumors (TT-00973 is a potential best-in-class novel AXL/FLT3 inhibitor; TT-01488 is a potential best-in-class, non-covalent, reversible BTK inhibitor), inflammation (currently collaborating with LG Chem to develop TT-01688 (a highly selective oral S1P1 modulator for the treatment of UC and AD) and developing TT-01025, a potential best-in-class irreversible VAP-1 inhibitor for the treatment of NASH) and cardiovascular metabolic diseases (developing TT-00920, the first potential best-in-class highly selective oral PDE9 inhibitor).
None of these sentences.
Main Business
Please use your Futubull account to access the feature.
Pharma block sciences currently has a pipeline of six clinical stage candidate products and one pre-clinical stage candidate product, and the company plans to continue expanding its pipeline.
The core product of Pharma Block Sciences, Tinengotinib (TT-00420), as a registered clinical-stage and potentially globally pioneering MTK inhibitor (mainly targeting FGFR/VEGFR, JAK, and Aurora kinases), has the potential to treat various relapsed or intractable, drug-resistant solid tumors (including cholangiocarcinoma, prostate cancer, breast cancer, biliary tract cancer and pan-FGFR solid tumors) to meet these unmet clinical needs. Tinengotinib has been granted China's National Medical Products Administration's breakthrough therapy designation and FDA's Fast-Track Designation for treatment of cholangiocarcinoma, as well as FDA's orphan drug designation for treatment of cholangiocarcinoma and EMA's orphan drug designation for treatment of biliary tract cancer.
In addition to the core products, the company is also advancing several clinical projects for tumors (TT-00973 is a potential best-in-class novel AXL/FLT3 inhibitor; TT-01488 is a potential best-in-class, non-covalent, reversible BTK inhibitor), inflammation (currently collaborating with LG Chem to develop TT-01688 (a highly selective oral S1P1 modulator for the treatment of UC and AD) and developing TT-01025, a potential best-in-class irreversible VAP-1 inhibitor for the treatment of NASH) and cardiovascular metabolic diseases (developing TT-00920, the first potential best-in-class highly selective oral PDE9 inhibitor).
The following table shows the drug pipeline of the company up to the last feasible date and summarizes the development status of the selected candidate drugs in the clinical and preclinical stages:
Shareholder Structure
According to the prospectus, Pharma block sciences' shareholder structure prior to listing was:
Dr. Wu Yongqian holds 12.54% of the shares directly;
Employee incentive platform Nanjing Yirui holds 14.34% of the shares;
Nanjing Jiminrui holds 7.41% of the shares;
Dr. Wu Yongqian is a general partner of Nanjing Yipu and Nanjing Jiminrui, controlling a total of 34.29% of the shares.
Pharma Block Sciences (300725.SZ), holds a 5.79% stake;
Morningside Venture (I) under the Chen Tanqing family trust holds a 7.24% stake through Jishi Development;
Advanced Manufacture Fund, holds a 6.36% stake;
CPE Investment, holds a 5.64% stake;
Restructuring Fund, holds a 4.23% stake;
Jinpu Health Fund II, Jinpu Health Fund III, holds a 3.79%, 0.70% stake respectively;
Guotou Chuangye, holds a 3.03% stake through Guotou Bay Area Fund, Guotou Chuangye Ningbo Fund;
Co-stone Venture Capital, holds a 2.04%, 1.27%, 0.65% stake respectively through Shenzhen Linghui, Wuhu Xingrui, and Nanjing Lingyi.
Changjiang National Holding holds 1.80% and 1.06% of shares respectively in Guohong Medical and Guohong Jiyuan.
China Merchants Capital Management holds 1.79% and 1.42% of shares respectively in Jingzhou Huikang and Guodiao China.
Enran Ruiguang and Nanjing Qiruiyoukang hold 0.87% and 0.53% of shares respectively.
Nanjing Zijin holds 2.95% of shares.
Shanghai State-owned Assets Management holds 2.18% of shares through Shanghai Guoxin.
Jiangbei Fund holds 2.00% of shares.
Nanjing Yingmeng holds 1.17% of shares.
Nanjing Jiangbei New Area Management Committee holds 1.09% of shares through Jiangbei Asset Management.
Wuxi Guolian Jintou Qiyuan holds 0.44% and 0.22% of shares respectively through Taixing Qichen and Jiangsu Zhongde.
Suzhou Dunxing Investment holds 0.13% and 0.09% of shares respectively through Jiangsu Dunhe and Suzhou Dunxing.
TIF Biomedical and Sanyizhongzhi hold 0.38% and 0.71% of shares respectively.
SIXTY DEGREE holds 0.70% of shares.
Lvyong Ruihua holds 0.65% of shares.
CR Life holds 0.55% of shares.
Eastern Handson holds 0.51% of shares.
Nanjing Baiyide holds 0.44% of shares.
Wuxi Ruitong holds 0.22% of shares.
BOC International holds 0.44% of shares through BOC Capital.
Board of directors and executives
Yaojia Ankang board of directors consists of seven directors, including:
Two executive directors: Dr. Wu Yongqian (Chairman and CEO) and Mr. Wu Di (Vice President).
Two non-executive directors: Ms. Jia Zhongxin and Dr. Yi Hua.
Three independent non-executive directors: Ms. Xu Haiyin, Ms. Zheng Zhelan, and Mr. Li Shupai.
Three members of the supervisory board: Ms. Zhao Weili, Mr. Mei Jianghua, and Ms. Pang Yajing.
In addition to executive directors, senior management consists of chief medical officer, Dr. Fang Jing, chief operating officer of TransThera US, Ms. Cui Songxi, vice president of operations, Dr. Peng Peng, vice president of project management, Dr. Sheng Zejuan, clinical executive director, Dr. Sun Caixia and board secretary, Ms. Feng Jie.
Corporate Performance
According to the prospectus, in 2022 and 2023, the operating revenue of PharmaDasciences was 124,000 and 1,181,000 RMB respectively, and the corresponding R&D costs were 263 million and 344 million RMB respectively. The corresponding net losses were 252 million and 343 million RMB respectively.
Intermediary Team
PharmaDasciences' IPO intermediaries include Citic Securities and Huatai International as its joint sponsors; Ernst & Young as its auditor; Jia Yuan and Mayer Brown as its China and Hong Kong legal counsel respectively; Jingtian & Gongcheng and Slaughter and May as its Chinese and Hong Kong legal counsel respectively; Foster Sullivan as its industry consultant.